South Dakota 2023 Regular Session

South Dakota Senate Bill SB122

Introduced
1/26/23  

Caption

Address the potential abuse of opiate and opioid drugs.

Impact

The legislation impacts existing regulations under chapter 34-20B concerning the prescribing of controlled substances. It proposes limits on the duration and quantity of opioid prescriptions, particularly for emergency patients, minors, and initial visits. For example, prescriptions for adults in an emergency room or clinic cannot exceed four days, while those issued to minors cannot exceed three days, thus fostering safer prescribing practices. If treatment extends beyond 30 days, additional checks are enforced including repeated examinations and a signed narcotics-use document from the patient, ensuring ongoing monitoring for safety and efficacy.

Summary

Senate Bill 122, introduced by Senator Frye-Mueller, seeks to curb the potential abuse of opioid drugs through stricter regulations on prescribing practices. The bill mandates that before practitioners can issue an initial prescription for a Schedule II opiate or opioid drug, they must inform patients about the risks, document the patient's medication history, conduct a physical examination, create a treatment plan, and offer the option of a lesser quantity of the drug. This process is designed to ensure that patients receive comprehensive care and are aware of the dangers associated with opioid medication use.

Contention

Despite the intent to reduce opioid misuse, the bill has sparked discussions among healthcare providers regarding its implications on patient care. Supporters argue that these measures will help mitigate the opioid crisis and protect patients from addiction risks, while opponents highlight concerns about potential barriers to legitimate pain management. They argue that the strict regulations might hinder access to necessary medications for patients with chronic pain, thus impacting their quality of life. Additionally, critics express unease over the burden placed on practitioners in terms of paperwork and compliance requirements, which could deter them from prescribing essential treatments.

Notable_points

The bill allows exemptions for patients receiving specific types of care, such as those in hospitals, cancer treatment, or palliative care, indicating a recognition of the need for comprehensive pain management methods in sensitive circumstances. It also provides clarity on the repercussions of violating the terms of the narcotics-use document, empowering practitioners to sever ties with non-compliant patients. This establishes a framework that prioritizes safety while attempting to balance the need for responsible pain management.

Companion Bills

No companion bills found.

Previously Filed As

SD HB07159

An Act Addressing Opioid Use.

SD HB05053

An Act Concerning Opioids And Access To Overdose Reversal Drugs.

SD HB07052

An Act Preventing Prescription Opioid Diversion And Abuse.

SD SB00352

An Act Concerning Prescriptions For And The Dispensing Of Opioid Antagonists And Opioid Drugs.

SD S2611

Opioid Alternatives

SD H7131

Opioid Alternatives

SD SB1109

Controlled substances: Schedule II drugs: opioids.

SD HB07395

An Act Concerning Opioid Abuse And Treatment.

SD HB0288

Opioid Dispensing Requirements

SD HB275

Regards patient prescription reports, opioids, medical marijuana

Similar Bills

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

CA AB852

Health care practitioners: electronic prescriptions.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

OK HB2676

Public health and safety; exempting certain practitioners from electronic prescription requirements for controlled dangerous substances; effective date.

AZ SB1254

Opioids; containers; labeling; requirements; repeal

AZ HB2291

Opioids; containers; labeling; requirements; repeal